Amiko Overview

  • Status
  • Private

  • Employees
  • 43


  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $4.2M

  • Investors
  • 3

Amiko General Information


Developer of a disease management platform designed to assist healthcare professionals and empower patients to achieve outcomes. The company's platform includes medication sensors that collect unique inhalation data to permit monitoring compliance with lung function and disease progression, enabling hospitals to access remote monitoring tools, AI-enabled therapy suggestions, and data analytics to make smarter decisions.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Therapeutic Devices
Other Industries
Other Healthcare Technology Systems
Corporate Office
  • Via Ruggiero Settimo 4
  • 20146 Milan(Milan)
  • Italy

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amiko Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Grant $4.2M 00.000 Completed Generating Revenue
4. Early Stage VC 18-Dec-2017 00000 00.000 0000 Completed Generating Revenue
3. Grant 08-Dec-2017 00.00 00.000 Completed Generating Revenue
2. Seed Round 27-Jan-2016 $1.73M $1.73M 00.000 Completed Product Development
1. Accelerator/Incubator 01-Jan-2016 Completed Generating Revenue
To view Amiko’s complete valuation and funding history, request access »

Amiko Cap Table

Stock # of Shares
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 00,000 000.00 000.00 00 000.00 00.00
To view Amiko’s complete cap table history, request access »

Amiko Comparisons

HQ Location
Total Raised
Post Valuation
Developer of a disease management platform designed to assist healthcare professionals and empower patients to achieve o
Therapeutic Devices
Milan, Italy
43 As of 2024
00000 00.000


irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nu
00000000000 0000000
Manchester, United Kingdom
00 As of 0000
000000000000 00000


ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercit
00000 0000000000 000
New Haven, CT
00 As of 0000
000000 - 000 0000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amiko Competitors (15)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Safey Accelerator/Incubator Backed Manchester, United Kingdom 00 00000 000000000000 00000
Wellinks Venture Capital-Backed New Haven, CT 00 0000 000000 - 000 0000
Cohero Health Formerly VC-backed New York, NY 0 000.00 000000&0 000.00
AllazoHealth Accelerator/Incubator Backed New York, NY 00 00000 000000000 - 00000
Portavita Formerly VC-backed Amsterdam, Netherlands 00 000000&0
You’re viewing 5 of 15 competitors. Get the full list »

Amiko Patents

Amiko Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4034207-A1 Dry powder inhaler for pulmonary or nasal delivery Active 27-Sep-2019 00000000000
US-20220305220-A1 Dry powder inhaler for pulmonary or nasal delivery Pending 27-Sep-2019 00000000000
EP-4034207-B1 Dry powder inhaler for pulmonary or nasal delivery Active 27-Sep-2019 00000000000
EP-4343776-A2 Dry powder inhaler for pulmonary or nasal delivery Pending 27-Sep-2019 00000000000 0
US-20200171251-A1 Accessory for an inhaler, inhaler and method for detecting a drug administration process Active 28-Jul-2017 A61M15/0065
To view Amiko’s complete patent history, request access »

Amiko Executive Team (5)

Name Title Board Seat Contact Info
Duilio Macchi Co-Founder & Chief Executive Officer
Alexander Marinov Co-Founder & Chief Financial Officer
Alessandro Fato Co-Founder & Chief Technology Officer
Martijn Grinovero Co-Founder, Chief Marketing Officer & Chief Commercial Officer
Roberto Lucini Project Development Manager
To view Amiko’s complete executive team members history, request access »

Amiko Signals

Growth Rate

0.80% Weekly
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers


Similarweb Unique Visitors


Majestic Referring Domains


PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amiko Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Sanner Ventures Family Office Minority 000 0000 000000 0
IBM Watson AI XPRIZE Other 000 0000 000000 0
EIT Digital Accelerator/Incubator Minority 000 0000 000000 0
To view Amiko’s complete investors history, request access »

Amiko FAQs

  • Who is the founder of Amiko?

    Duilio Macchi, Alexander Marinov, Alessandro Fato, and Martijn Grinovero are the founders of Amiko.

  • Who is the CEO of Amiko?

    Duilio Macchi is the CEO of Amiko.

  • Where is Amiko headquartered?

    Amiko is headquartered in Milan, Italy.

  • What is the size of Amiko?

    Amiko has 43 total employees.

  • What industry is Amiko in?

    Amiko’s primary industry is Therapeutic Devices.

  • Is Amiko a private or public company?

    Amiko is a Private company.

  • What is Amiko’s current revenue?

    The current revenue for Amiko is 00000.

  • How much funding has Amiko raised over time?

    Amiko has raised $2.23M.

  • Who are Amiko’s investors?

    Sanner Ventures, IBM Watson AI XPRIZE, and EIT Digital have invested in Amiko.

  • Who are Amiko’s competitors?

    Safey, Wellinks, Cohero Health, AllazoHealth, and Portavita are some of the 15 competitors of Amiko.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »